Across TCGA pan-cancer cohorts, MIR17HG Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MIR17HG data layer compared with 22 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MIR17HG Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MIR17HG expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, CESC, and KIRC are the cancer types where MIR17HG Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.079	0.768	<.001	48	view →
CESC	OS	Median	All	0.089	0.585	.025	6	view →
KIRC	DFS	Median	II,III,IV	0.146	0.693	.021	6	view →
UCEC	DFS	Median	All	1.000	0.628	.023	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: MIR17HG tumor-vs-normal RNA expression · all MIR17HG data types